â– LECTURE OVERVIEW: Neonatal Respiratory Distress Syndrome (RDS) is a major cause of respiratory distress in premature infants, most commonly caused by surfactant deficiency.
â– MOLECULAR PHYSICS & COLLAPSE:
1. Type II pneumocytes: Synthesize surfactant, a phospholipid-rich substance (primarily dipalmitoylphosphatidylcholine), starting around 28 weeks gestation.
2. Surface Tension: Surfactant coats alveoli, reducing surface tension.
3. Laplaces Law (P = 2T/r): In surfactant deficiency, high surface tension (T) causes small alveoli to experience high pressure (P), collapsing into them (atelectasis) on expiration.
4. Intrapulmonary Shunt: Alveolar collapse causes ventilation-perfusion mismatch, leading to hypoxia, hypercapnia, and acidosis.
5. Hyaline Membranes: Acidosis damages endothelial tissues, spilling fibrin-rich fluid that forms pink hyaline membranes on histology.
â– PHARMACOKINETIC & PHARMACODYNAMIC ATTRIBUTES:
Absorption and steady-state kinetics display high variability based on plasma protein binding levels, tissue volume of distribution (Vd), and hepatic CYP450 microsomal enzymatic clearance indices.
â– CLINICAL REGISTRY INSIGHTS:
Patient registry reviews depict high clinical validity in diverse populations, indicating highly correlated trends of symptom development and treatment responsiveness.
[HY-BOARD-1012]
🌟 Dynamic Clinical Key:
Presents at birth with tachypnea, nasal flaring, grunting, and intercostal retractions. Chest X-ray reveals a classic ground-glass appearance with air bronchograms. Incidence is reduced by giving antenatal corticosteroids (Dexamethasone) before preterm delivery to mature type II cells. Closely monitor serum plasma concentrations if drugs display a narrow therapeutic window to mitigate toxic peaks. Assess demographic representation when applying trial results to real-world patients.